<DOC>
	<DOCNO>NCT00101595</DOCNO>
	<brief_summary>The purpose clinical research study learn BMS-354825 activity define hematologic response subject lymphoid blast phase chronic myeloid leukemia ( CML ) Philadelphia chromosome positive acute lymphoblastic leukemia primary acquire resistance imatinib mesylate .</brief_summary>
	<brief_title>Dasatinib ( BMS-354825 ) Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Subjects Philadelphia chromosome positive ( Ph+ ) ( BCR/ABL+ ) lymphoid blast phase chronic myeloid leukemia whose disease primary acquire hematologic resistance imatinib mesylate intolerant imatinib mesylate . Subjects consider lymphoid blast phase CML meet least one follow criterion : *30 % lymphoid blast peripheral blood bone marrow . *Extramedullary infiltrates leukemic cell ( spleen liver ) peripheral blood lymphoid blast morphology . ECOG performance status score 02 . Adequate hepatic function define : *Total bilirubin less equal 2.0 time institutional upper limit normal ; *alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) less equal 2.5 time institutional upper limit normal . Adequate renal function define : *serum creatinine less equal 1.5 time institutional upper normal limit . Men woman , 18 year age old . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study period least 1 month least 3 month study manner risk pregnancy minimize . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IC/L equivalent unit HCG ) within 72 hour prior start study medication . WOCBP unwilling unable use acceptable method avoid pregnancy entire study period least 1 month least 3 month completion study medication . WOCBP use prohibit contraceptive method ( applicable ) . Women pregnant breastfeeding . Women positive pregnancy test enrollment prior study drug administration . Men whose sexual partner WOCBP , unwilling unable use acceptable method avoid pregnancy partner entire study period least 3 month completion study medication . Subjects eligible willing undergo transplantation screen period . A serious uncontrolled medical disorder active infection would impair ability subject receive protocol therapy . Demential alter mental status would prohibit understanding rendering informed consent . History significant bleeding disorder unrelated CML . Concurrent incurable malignancy CML . Evidence organ dysfunction digestive dysfunction would prevent administration study therapy . Subjects receive follow : imatinib mesylate within 7 day ; interferon cytarabine within 14 day ; target small molecule anticancer agent within 14 day ; investigational antineoplastic agent hydroxyurea anagrelide within 28 day start treatment BMS354825 . Subjects currently take drug generally accept risk cause Torsades de Pointes . Subjects take medication irreversibly inhibit platelet function . Prior therapy BMS354825 . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Lymphoid blast phase chronic myeloid leukemia</keyword>
	<keyword>Philadelphia chromosome positive acute lymphoblastic leukemia</keyword>
</DOC>